A Phase I Study of Single-centre, Open-label clinical trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs HG-146 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors HitGen
- 07 Aug 2019 Planned End Date changed from 12 Dec 2019 to 12 Jul 2020.
- 07 Aug 2019 Planned primary completion date changed from 12 Jul 2019 to 12 Dec 2019.
- 26 May 2019 Status changed from active, no longer recruiting to recruiting.